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https://doi.org/10.1016/j.ccell.2019.08.003SUMMARYThemetastatic process of colorectal cancer (CRC) is not fully understood and effective therapies are lacking.
We show that activation of NOTCH1 signaling in the murine intestinal epithelium leads to highly penetrant
metastasis (100% metastasis; with >80% liver metastases) in KrasG12D-driven serrated cancer. Transcrip-
tional profiling reveals that epithelial NOTCH1 signaling creates a tumormicroenvironment (TME) reminiscent
of poorly prognostic human CRC subtypes (CMS4 and CRIS-B), and drives metastasis through transforming
growth factor (TGF) b-dependent neutrophil recruitment. Importantly, inhibition of this recruitment with clin-
ically relevant therapeutic agents blocks metastasis. We propose that NOTCH1 signaling is key to CRC pro-
gression and should be exploited clinically.INTRODUCTION
Patient mortality in CRC is closely associated with metastasis
(Jemal et al., 2011), with an overall 5-year survival rate for late-
stage patients of 5%–10%. Resection of both primary and met-Significance
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prognosis subtypes and of metastatic seeding at the secondar
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Stratification of CRCby transcriptional profiling (Guinney et al.,
2015) has allowed classification of CRC into four consensus
molecular subtypes (CMSs). CMS1 tumors are likely to bemicro-
satellite unstable, hyper-mutated, and characterized by lympho-
cytic infiltration. CMS2 and CMS3 tumors exhibit high levels of
WNT signaling, little immune infiltration and intermediate overall
and relapse-free survival. Patients with ‘‘mesenchymal’’ CMS4
tumors have the worst overall and relapse-free survival rate
and these tumors are characterized by significant fibroblast
and innate immune cell infiltration, and elevated TGF-b signaling
(Dienstmann et al., 2017; Becht et al., 2016a). As these transcrip-
tional signatures are generated fromwhole tumors, the presence
of stromal cells contributes significantly (Calon et al., 2015; Isella
et al., 2015; McCorry et al., 2018), confounding analysis. While
the contribution of epithelial cells to stromal infiltration/adapta-
tion is not fully understood (Wellenstein and de Visser, 2018),
cell-intrinsic transcriptional signatures (CRIS) have been shown
to have prognostic implications (Dunne et al., 2017; Isella et al.,
2017). In particular, the CRIS-B signature predicts poor prog-
nosis and is enriched for signatures associated with epithelial-
mesenchymal transition (EMT) and TGF-b signaling. Notably,
while CMS4 and CRIS-B are characterized by the same acti-
vated programs, the composition of gene signatures is different
and CRIS-B is a composition of mainly CMS1 and CMS4 genes.
Crucially, mutational data does not stratify the different CRC
subtypes and the mechanisms which drive subtypes are not
known (Guinney et al., 2015).
There are two postulated routes by which metastatic CRC
(mCRC) arises. The classical route is initiated by mutations in
the APC tumor suppressor gene which is followed by alterations
in mitogen-activated protein kinase (MAPK), TP53, and TGF-b
signaling during progression (Fearon and Vogelstein, 1990).
These tumors develop from adenomas with tubular morphology
(Fearon, 2011). Recent efforts to model metastatic disease with
compounding mutations in the intestine of APC-deficient mice
yielded tumors that readily progressed to adenocarcinoma but
showed limited metastasis (Sakai et al., 2018). Intriguingly, if
APC-deficient tumors with compounding mutations are propa-
gated ex vivo as organoids and re-implanted into mice, metas-
tasis occurs (Tauriello et al., 2018; de Sousa e Melo et al.,
2017; O’Rourke et al., 2017). Alternatively, CRC progression
can be initiated by KRAS or BRAF mutations, with tumor devel-
opment from adenomas with a serrated morphology (Jass et al.,
2002). Importantly, patients with serrated adenoma-associated
signatures have a poorer prognosis than those with ‘‘classical’’
tubular adenomas (De Sousa et al., 2013). These adenomas
may progress to high-grade carcinoma through p16/CDKN2A
promoter hyper-methylation and subsequent gene silencing, or
via mutation of TP53 (IJspeert et al., 2015). Braf-mutant geneti-
cally engineered mouse models (GEMMs) of CRC exhibit acti-
vated WNT signaling, indicated by nuclear accumulation of
b-catenin, while KRAS-mutant tumors appear to develop inde-
pendently of WNT pathway activation (Bennecke et al., 2010;
Janssen et al., 2002; Trobridge et al., 2009). Nevertheless, these
GEMMs develop few distant metastases and have a long
latency.
Despite some caveats, GEMMs are powerful tools to study tu-
mor biology in an autochthonous setting, and are the gold stan-
dard in preclinical CRC research. The major weakness of current320 Cancer Cell 36, 319–336, September 16, 2019CRC GEMMs is the lack of a complete adenoma-carcinoma-
metastasis cascade and the absence of highly penetrant metas-
tases, particularly to distant organs such as the liver (Jackstadt
and Sansom, 2016; Romano et al., 2018). For this reason, current
models can be seen as excellent tools to study early-stage dis-
ease rather than malignant progression, with transplantation of
tumor-derived organoids currently being the best alternative
for analysis of metastatic spread (Romano et al., 2018; Tauriello
et al., 2018). Transplantation models have highlighted a key role
for LGR5+ stem cells in metastasis (de Sousa e Melo et al., 2017)
and have suggested that TGF-b inhibitors may have efficacy in
Apc-mutation-driven mCRC (Tauriello et al., 2018).
Activated NOTCH1 signaling has been observed in CRC and
other cancer types (Sancho et al., 2015; Noah and Shroyer,
2013; Irshad et al., 2017). This activation can occur via NOTCH1
ligands on the surface of tumor cells or by components of the
TME such as endothelial or innate immune cells (Meurette and
Mehlen, 2018). Tumor cell-autonomous signaling can also occur
by NOTCH1 receptor copy-number gain, reported in 22% of
CRCs, with negative prognostic value (Arcaroli et al., 2016). In
addition NOTCH1 signaling can be activated via mutation of
FBXW7, found in 11% of human CRCs (Cancer Genome Atlas
Network, 2012; Babaei-Jadidi et al., 2011). Activation of
NOTCH1 signaling can contribute to cancer cell stemness, inva-
sion, and metastasis (Lu et al., 2013; Sonoshita et al., 2011,
2015; Rodilla et al., 2009; Wieland et al., 2017). Moreover, recent
combination of activated NOTCH1 signaling and Trp53 deletion
in the intestine resulted in metastatic disease, albeit with long la-
tency and relatively low penetrance (10% liver metastases)
(Chanrion et al., 2014), limiting preclinical relevance. Importantly,
the molecular mechanism driving NOTCH1-dependent metas-
tasis and the requirement for additional oncogenic driver muta-
tions remains unclear.
There is an urgent need for improved therapeutic options
for patients with advanced mCRC. Currently, molecular subtyp-
ing is the most effective strategy to identify patients with the
poorest prognosis. For this reason, subtype-specific preclinical
models are vital for development of new therapeutic
approaches.
RESULTS
Mutation Context-Dependent Ability of NOTCH1 toDrive
Intestinal Cancer Metastasis
Given associations between NOTCH signaling and CRC we
generated a NOTCH-score (Kwon et al., 2016), based on expres-
sion of pathway components, and applied this to The Cancer
Genome Atlas (TCGA) human CRC dataset (Cancer Genome
Atlas Network, 2012). We found that a high NOTCH-score is
significantly associated with CMS4 and poor prognosis (Figures
S1A and S1B). Interestingly, when further stratified, the NOTCH-
score remained prognostic when KRAS was mutated (Fig-
ure S1C), and segregated the poorest prognosis patients in
CMS4 (Figure S1D). In addition, we found a high percentage of
human CRC metastasis strongly positive for NOTCH1 intracel-
lular domain (N1ICD), indicative of activated NOTCH1 signaling
in human CRC metastasis (Figure S1E).
In light of these observations, we sought to test the functional
role of NOTCH1 signaling in CRC. This was achieved using the
Figure 1. NOTCH1 Drives Intestinal Metastasis in an Autochthonous Model
(A) Schematic description of genetic crossing strategies. Cre, cre-recombinase; ER, estrogen receptor; loxP, Cre-Lox recombination site; IRES, internal ribosome
entry site.
(B) Kaplan-Meier survival curves of intestinal tumor free survival; PN, n = 21; AP, n = 10; APN, n = 12; KP, n = 15; KPN, n = 31.
(C) Incidence of metastases (%) per genotype; PN, n = 21; AP, n = 10; APN, n = 12; KP, n = 14; KPN, n = 29. DIA, diaphragm; LN, lymph-node; Peri, peritoneal
carcinomatosis.
(D and E) Number (D) and burden (E) of macroscopic metastases of KPN mice. Error bars represent mean ± SEM.
(F) Left image: representative image of macroscopic liver metastatic burden of KPN mice. Right images: representative H&Es of KPN metastases. Scale
bars, 100 mm.
See also Figures S1 and S2.inducible enterocyte-specific villinCreER to recombine either
one copy of Apcfl/+ or activate KrasG12D/+ in combination with
deletion of Trp53fl/fl, and overexpression of the transcriptionally
active N1ICD (Figure 1A). Consistent with previous studies,
villinCreER Trp53fl/fl Rosa26N1icd/+ (PN) mice (Chanrion et al.,
2014) developed tumors at long latency (Figure 1B). Importantly,
all induced villinCreER KrasG12D/+ Trp53fl/fl Rosa26N1icd/+ (KPN)
mice that developed intestinal adenocarcinoma exhibited
metastases to lymph nodes, lungs, liver, and/or diaphragm
at clinical endpoint (Figure 1C). A total of 83% (24/29) of
KPN mice had liver metastases, recapitulating human disease
(Figures 1D-1F). In contrast, APC-deficient models such
as villinCreER Apcfl/+ Trp53fl/fl Rosa26N1icd/+ (APN) or villinCreERApcfl/+ Trp53fl/fl (AP) did not develop metastases. PN or
villinCreER KrasG12D/+ Trp53fl/fl (KP) mice developed few metas-
tases and very rarely to distant sites: 5% liver and ~20% lymph
nodes, respectively (Figure 1C). Expression of two copies of the
N1icd allele (Figure S2A) or one copy of mutant Trp53fl/R172H in
KPNmice did not change survival and/or metastatic burden (Fig-
ures S2B and S2C). Furthermore, mutations had only a mild
impact on intestinal homeostasis (Figures S2D–S2G). Given
that KP and KPN mice exhibited similar latency (Figure 1B), but
only KPN mice displayed significantly increased metastatic
burden (Figure 1C), we concluded that epithelial NOTCH1 drives
metastasis in a setting where Trp53 is mutated and RAS/MAPK
signaling is activated.Cancer Cell 36, 319–336, September 16, 2019 321
KPN Tumors Are of Serrated Origin
Human serrated CRCs have been associated with KRAS muta-
tions (IJspeert et al., 2015), and these morphological features
are reported to be recapitulated in the tumors of KrasG12D-driven
intestinal GEMMs (Bennecke et al., 2010). Histological analysis
of KPN tumors confirmed a serrated morphology of primary tu-
mors, while tumors driven by Apc deletion exhibited a tubular
morphology (Figure 2A). Consistent with the metastatic spread
of KPN tumors, primary tumors were highly invasive and poorly
differentiated, exhibited a high collagen content, significant
infiltration of cancer associated fibroblasts (CAFs) and hypoxia,
all features typical of advanced disease (Figures 2B–2D). On
average, KPN mice developed two tumors per intestine (Figures
2E, 2F, and S3A). We analyzed the expression of the DNA
mismatch repair protein MLH1 in primary tumors of APN and
KPNmice. Retained expression of MLH1 indicates that these tu-
mors are microsatellite stable (MSS) (Figure S3B). Therefore,
KPN tumors represent models of MSS serrated intestinal cancer
in which NOTCH1 signaling drives metastasis without impacting
tumor initiation.
Alteration ofWNTSignaling in theMetastatic KPNModel
Human serrated polyps show reduced WNT pathway activity
compared with tubular adenomas which harbor APC mutations
(Figure 3A) (Borowsky et al., 2018; Bennecke et al., 2010). Com-
parison of WNT target gene expression between GEMM primary
tumors and human serrated adenoma (Fessler et al., 2016) re-
vealed that KPs and KPNs are closely related to serrated tumors
(Figure 3B). APN tumors exhibited significant activation of ca-
nonical WNT signaling, indicated by nuclear accumulation of
b-catenin, with lower activation observed in KPN tumors (Fig-
ure 3C). This was reflected by distinct patterns of WNT target
gene expression in each primary tumor type (Figures 3B, 3D,
and S3B). Moreover, liver metastases from KPN tumors did not
have a marked accumulation of nuclear b-catenin, although
elevated expression of some WNT targets, including CD44 and
SOX9, was observed (Figures 3C and S3C). This recapitulates
activation of WNT seen in human serrated tumors and indicates
that hyper-activation of epithelial canonical WNT signaling is not
essential for metastasis.
Given these moderate levels of WNT signaling and reported
upregulation of WNT ligands or R-spondins in CRC (Seshagiri
et al., 2012), we examined ligand deregulation or ligand depen-
dence in our models. RNA-sequencing data exhibited profound
expression of WNT ligands (Figure S3D). To test ligand function-
ality we treated KPN mice with LGK974, a clinically relevant
PORCUPINE inhibitor, from 85 days after induction, blocking
WNT ligand secretion (Liu et al., 2013) (Figures 3E and S3E).
This treatment had no impact on survival or metastatic rate (Fig-
ures 3F and 3G; Table S1). To understand the mechanism of
WNT ligand independence, we derived organoid cultures from
KPN primary tumors. When these organoids were passaged or
seeded as single cells, they grew independently of WNT agonist
R-spondin1 and were refractory to LGK974 treatment (Figures
3H–3J). Similarly, KP organoids were refractory to LGK974 treat-
ment indicating a NOTCH1-independent mechanism (Fig-
ure S3F). This suggests an epithelial cell-intrinsic mechanism
of WNT ligand-independent growth, or independence from
WNT signaling altogether. To identify drivers of WNT activation,322 Cancer Cell 36, 319–336, September 16, 2019we applied whole-genome sequencing to ten KPN primary tu-
mor-derived organoid lines. This approach confirmed loss of
Trp53 and MSS status (overall 1.59 mutations/Mb; coding muta-
tion rate 1.31 mutations/Mb) (Figures S4A–S4C and Table S2).
Strikingly, four out of ten (40%) organoid lines had homozygous
mutations inCsnk1a1 (encoding casein kinase 1a), a component
of the b-catenin destruction complex (Figure 3K). Intriguingly,
Csnk1a1 deletion in intestinal epithelial cells has been shown
to trigger tumorigenesis only in combination with loss of Trp53
(Elyada et al., 2011). Furthermore, two lines showed Ephb2
missense mutations (Figure 3K), which has been associated
with CRC progression (Batlle et al., 2005; Clevers and Batlle,
2006). Importantly, while these mutations drive increased
expression of selected WNT targets, they appear to be weaker
activators of the pathway than Apc loss and critically mimic
levels found in human serrated tumors.
Epithelial NOTCH1 Drives Subtypes of Human CRC with
Poorest Prognosis
To better understand how our model, and more broadly,
NOTCH1 signaling relates to human CRC, we generated
transcriptome-wide expression profiles from tumor tissue (con-
sisting of epithelium and stroma). Comparison of signatures
generated from both the serrated (KPN) and tubular (APN)
tumors (Table S3) with human data revealed a poorer prognosis
for patients resembling the KPN signature (Figure 4A), in line with
the poor prognosis associated with human serrated CRC (De
Sousa et al., 2013). Interestingly, when we analyzed organoid
expression profiles derived from APN or KPN tumors (Table
S4) this survival segregation still holds (Figure 4B), demon-
strating the predictive value of epithelial KPN signatures. Com-
parison of mouse intestinal tumors with CMSs revealed a
NOTCH1-dependent positive correlation between the KPN tran-
scriptome and CMS4, and a negative correlation with CMS2/3
(Figure 4C). Strikingly, tumor models driven by APC loss corre-
late with CMS2/3 (Figure 4C), which confers better disease prog-
nosis (Guinney et al., 2015). Moreover, cross-comparison with
CRIS signatures revealed that KPN tumors strongly correlate
with CRIS-B (Figure 4D), associated with poor prognosis (Isella
et al., 2017). Gene set enrichment analysis (GSEA) indicates
that KPN tumors are enriched for CMS4/CRIS-B-associated sig-
natures such as vascular endothelial growth factor/vascular
endothelial growth factor receptor, EMT, and TGF-b activation
(Figures 4E and S4D; Table S5). These data demonstrate that
the GEMMs described here exhibit transcriptional overlap with
the subset of human CRCs with poorest prognosis and that
epithelial NOTCH1 is a key driver of those subtypes.
Epithelial NOTCH1 Controls Neutrophil Recruitment to
Drive Metastasis
The current paradigm suggests that stromal signatures are asso-
ciated with poor prognosis, which is particularly pertinent to the
‘‘mesenchymal’’ CMS4 tumor signature. In light of this, we have
compared our transcriptional profiles with data used to charac-
terize human CMS4 CRC as highly enriched for myeloid, angio-
genic, inflammatory, fibroblast, and immunosuppressive cell
signatures (Becht et al., 2016a, 2016b). While many of these fea-
tures were recapitulated in metastatic KPN tumors (Figure 5A),
most were also present in the non-metastatic KP model (Figures
Figure 2. Morphological Analysis of Primary Tumors
(A) Representative H&E images of primary tumors. Scale bars, 100 mm. Arrows indicate serrated morphology.
(B) Representative images of indicated markers on primary tumors. Scale bars, 100 mm.
(C and D) Tumor stage (C) and differentiation at endpoint (D).
(E) Macroscopic primary tumors per mouse.
(F) Macroscopic primary tumor burden per mouse.
In (C–F): AP, n = 10; APN, nR 11; KP, n = 14; KPN, nR 22. Error bars in (E and F) represent mean ± SEM. See also Figure S3.
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Figure 3. Role of WNT Signaling in Metastatic KPN Tumors
(A) Expression of WNT targets in human tubular or serrated adenoma.
(B) Heatmap of a human serrated signature versus mouse primary tumor signatures.
(C) b-Catenin IHC of primary tumors. M, metastases; L, liver; PT, primary tumor. Scale bars, 100 mm. Right bottom: quantification of nuclear b-catenin in primary
tumors (nR 10).
(D) Quantification of in situ hybridization (ISH) for positive cells on primary tumors (APN, nR 5; KPN, nR 7).
(legend continued on next page)
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Figure 4. Cross-Comparison and Subtyping
of GEMMs to Human CRC
(A) Recurrence-free survival (RFS) of CRC patients
stratified using a KPN versus APN tumor signature,
for patients of all four CMSs.
(B) RFS of CRC patients stratified using a KPN
versus APN organoid signature, for patients of all
four CMSs. In (A) and (B), the blue line shows
correlation %0.1 (low), the red line shows correla-
tion >0.1 (high).
(C) Heatmap showing expression correlation of in-
testinal cancer GEMMs with patient-derived CMSs.
p value for CMS4-KPN versus CMS4-KP correlation
(p = 0.003) was obtained using a Fisher r-z trans-
formation.
(D) Heatmap showing expression correlation of in-
testinal cancer GEMMs with patient-derived CRISs.
(E) GSEA results for GEMMs and CMS1-4 CRC
patient tumors. Replicates in (A–E), AP (tumors),
n = 3; APN (tumors), n = 3; APN (organoids), n = 4;
KP (tumors), n = 3; KPN (tumors), n = 9; KPN (or-
ganoids), n = 3.
See also Figures S3 and S4 and Tables S3, S4,
and S5.5A and S4E), implying that they may not be determinants of met-
astatic spread. Importantly, enrichment of a neutrophil signature
was associated with metastatic KPN tumors, but not with non-
metastatic KP tumors (Figures 5B and S4E). Similar to human
serrated adenoma, we have detected neutrophil accumulation
in primary tumors, metastases, and systemically in KPN mice
(Figures 5C–5F). Given that metastasis in the KPN model was
associated with neutrophil infiltration, we assessed expression
of chemokines implicated in neutrophil attraction (Figures 5G(E) Schematic representation of LGK974 treatments started 85 days after induction.
(F) Kaplan-Meier survival curves of KPN mice after treatment as indicated in (E).
(G) Incidence of metastases per treatment; in (F) and (G): vehicle, n = 7; LGK974, n = 8.
(H) Representative pictures of organoid cultures. R, R-spondin; E, EGF; N, Noggin. Scale bars, 100 mm.
(I) Organoid size or number 7 days after single-cell seeding under the indicated conditions. Samples were
(J) Organoid size or number 7 days after single-cell seeding under the indicated conditions. Samples were
(K) Analysis of the consequences of somatic mutations identified by whole-genome sequencing of KPN pr
Error bars in (A), (D), (I), and (J) represent mean ±SEM. Data in (A) and (D) analyzed byMann-Whitney U test, t
and S2.
Canceand S5A) finding increased expression of
Cxcl5 in the epithelium of KPN tumors but
not of KP (Figures 5G and 5H and Table
S6). Cxcl5 expression was correlated with
that of its receptorCxcr2, which is predom-
inantly expressed on neutrophils (Fig-
ure S5B). When we examined the expres-
sion of neutrophil-associated genes such
as ELANE, MPO, and CXCR2 in human
CRC, we found significantly increased
expression in human CMS4 (Figure S5C).
In addition, the neutrophil infiltration-score
was able to predict survival in treatment-
naive metastases and is significantly asso-
ciated with CMS4 and CRIS-B (Figures
S5D and S5E). Furthermore, neutrophilinfiltration of metastases, analyzed by MPO or CXCR2 expres-
sion predicts poor survival in an additional cohort (Figure S5F; Ta-
ble S6). For these reasons, we hypothesized that neutrophilsmay
be a critical driver of NOTCH1-dependent metastasis in CMS4/
CRIS-B CRC.
To test this, we treated KPN mice with AZD5069, a clinically
relevant CXCR2 small-molecule (CXCR2sm) inhibitor (Nicholls
et al., 2015), which has been shown to block neutrophil recruit-
ment. Importantly, while CXCR2sm treatment, from day 85generated from individual tumors, n = 3.
generated from individual tumors, n = 4.
imary tumor-derived organoids.
wo-tailed. See also Figures S3 and S4 and Tables S1
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Figure 5. Epithelial NOTCH1 Controls Neutrophil Recruitment to Drive Metastasis
(A) Heatmap showing standardized infiltration-scores (calculated with MCPcounter) in GEMM tumors; AP, n = 3; APN, n = 3; KP, n = 3; KPN, n = 9.
(B) Dot-plots showing standardized infiltration scores of neutrophils (calculated with MCPcounter); replicates as in (A).
(legend continued on next page)
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post induction, did not impact survival or primary tumor burden
in KPN mice, it profoundly reduced metastasis (Figures 5I, S6A,
and S6B; Table S1). Short term treatment of KPN tumor-bearing
mice with CXCR2sm resulted in reduced neutrophil counts in
both the peripheral blood and primary tumors (Figures 5J and
5K), and an increase in CD8+ T cell numbers, compared with
vehicle-treated counterparts (Figures 5K and S6C–S6E). The
enhanced CD8+ T cell number, thought to create an anti-meta-
static microenvironment at a secondary site, was retained in
livers at endpoint (Figure S6F).
Given that CXCR2 expression may not be restricted to neutro-
phils, we evaluated the impact of neutrophil depletion with a
Ly6G-targeting antibody (1A8). Again, metastasis was sup-
pressed when compared with isotype control (2A3), but survival
was unaffected (Figures 5I, S6G, and S6H; Table S1). Circulating
neutrophils were reduced at endpoint, indicating a sustained
effect of the neutralizing antibody (Figure S6I). We detected an
increase in CD4+ and CD8+ T cells in the primary tumors of
KPN mice treated with 1A8 in the short term (Figures 5K, S6J,
and S6K), and increased CD8+ T cells in livers at endpoint (Fig-
ure S6L). Together, this indicates that epithelial NOTCH1 triggers
CXCR2-dependent Ly6G+ neutrophil accumulation within the
pre-metastatic niche and generates an immunosuppressive
environment. Therapeutic targeting of neutrophils results in
increased infiltrating CD8+ T cells within the pre-metastatic niche
and a reduction in metastasis.
Epithelial NOTCH1 Signature Predicts Poor Survival and
Drives Epithelial TGF-b2 Expression
To determine how epithelial NOTCH1 controls metastasis, we
examined the transcriptome of tumor-derived KPN versus KP
organoids (Figure 6A; Table S7). Increased expression of canon-
ical NOTCH1 target genes, such as Fjx1 and Dtx1, along with an
enriched NOTCH-score was observed in KPN organoids,
compared with KP counterparts (Figures 6A and S7A). Strikingly
in human CRC, the KPN/KP-score predicts poor prognosis and
is associated with CMS4, CRIS-B, and neutrophil infiltration (Fig-
ures 6B and S7B–S7E). Interestingly, we found significantly
increased expression of the gene encoding the Tgfb2 ligand in
KPNorganoids (Figure 6A). TGFB2 expression predicts poor sur-
vival and is significantly correlated with CRIS-B, CMS4, NOTCH-
score, and KPN/KP-score in human CRC datasets (Figures 6B,
6C, and S7F–S7J). Furthermore, TGFB2 expression and the
KPN/KP-score are also associated with human serrated ade-
noma (Figure 6D). Together, these data demonstrate a strong
association between epithelial NOTCH1-dependent transcrip-(C) Blood neutrophil count at endpoint of indicated genotype (nR 6).
(D) Representative Ly6G IHC. Scale bars, 100 mm.
(E) Neutrophil infiltration-score in human adenoma.
(F) Quantification of Ly6G+ and S100A9+ cells per field of view (FOV); AP, n = 6;
(G) Representative ISH of Cxcl5 expression. Scale bars, 100 mm.
(H) Quantification of Cxcl5+ and Cxcr2+ cells; AP, n = 8; APN, n = 6; KP, n = 6; K
(I) Incidence of metastases at endpoint for KPN mice treated with: vehicle, n =
two-tailed.
(J) Blood neutrophil count after 1 week of indicated treatments: vehicle, n = 5; CX
tailed.
(K) Quantification of IHC on primary tumors of KPN mice after 1 week of indicate
Error bars in (B), (C), (E), (F), (H), (J), and (K) represent mean ± SEM. Data in (B), (
Figures S5 and S6 and Tables S1 and S6.tional signatures and high TGFB2 expression in serrated tumors
which exhibit poor outcome and underscores the human rele-
vance of the KPN model.
To understand how NOTCH1 controls Tgfb2 expression we
confirmed NOTCH1-dependent expression of Tgfb2 in KPN
organoids (Figure 6E). Moreover, GSEA showed that KPN pri-
mary tumors and organoids are associatedwith TGF-b activation
(Figures 4E and 6F). Promoter analysis of the genomic area
around the Tgfb2 transcriptional start site for putative RBPJ
binding sites revealed a number of canonical RBPJ-DNA binding
motifs (Figure 6G; Table S8). Chromatin immunoprecipitation of
RBPJ, the key mediator of NOTCH1-mediated transcription,
showed binding to the promoter of Tgfb2 in KPN organoids;
however, no binding was detected to an upstream region of
the Tgfb2 promoter which lacks RBPJ binding sites or a control
region (Chrm1) (Figure 6H).
Alongside the upregulated neutrophil markers in the primary
tumors from our GEMMs (Figures 5A–5D and 6I), Tgfb2 was
expressed by epithelial cells in KPN tumors (Figure 6J). Tgfb1
expression was comparable in both primary tumors and organo-
ids derived from KPN or KP mice (Figures 6A, 6E and 6I),
with predominantly stromal expression in KPN tumors
(Figure S7K).
Neutrophil Inhibition Attenuates Metastasis by T Cell
Activation
We next examined the contribution that the epithelial compart-
ment of KPN tumors makes to the TME in metastatic coloniza-
tion. Previous studies have reported that intra-splenic transplan-
tation of organoids frommouse intestinal tumors, with combined
Apc, KrasG12D, Trp53, and TGF-b signaling mutations, is the
most efficient means of generating metastases (Tauriello et al.,
2018; Sakai et al., 2018) (Figure 7A). We found no difference in
the capacity to colonize the liver between organoids derived
from KPN or villinCreER Apcfl/fl KrasG12D/+ Trp53fl/fl TrgfbrIfl/fl
(AKPT) tumors (Figure 7B), but found a significant increase in
Ly6G+ neutrophils in liver metastases formed by KPN organoids
(Figures 7C and 7D), and strong epithelial expression of Tgfb2
only in KPN liver metastases (Figure 7E).
To investigate the impact of neutrophils on metastatic seed-
ing of KPN organoids in this transplantation model we treated
recipient mice with either CXCR2sm or a TGFBR1/ALK5 kinase
inhibitor (Alk5i) (Figure 7F). Strikingly, both inhibitors reduced
the metastatic number and burden significantly (Figures 7G
and S7L), and, as observed in the autochthonous GEMM
(Figure S6C), long-term treatment with CXCR2sm led to aAPN, nR 5; KP, nR 4; KPN, nR 5.
PN, nR 6.
11; CXCR2sm, n = 10; 2A3, n = 10; 1A8, n = 9; analyzed by chi-square test,
CR2sm, n = 7; 2A3, n = 5; 1A8, n = 5; analyzed by Mann-Whitney U test, one-
d treatments: vehicle, nR 4; CXCR2sm, n = 7; 2A3, n = 5; 1A8, n = 5.
C), (E), (F), (H), and (K) analyzed by Mann-Whitney U test, two-tailed. See also
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Figure 6. Epithelial NOTCH1 Drives Poor Prognosis Signatures and TGF-b2 Expression
(A) Volcano-plot of organoid KPN (n = 3) versus KP (n = 3) mRNA expression.
(B) RFS of CRC patients (TCGA), stratified using the KPN/KP-score as in (A) or TGFB2 expression. The blue line shows expression%median score (low), the red
line shows expression > median score (high).
(C) Correlation of the KPN/KP-score and TGFB2 expression in human serrated adenoma (top) or in TCGA data (bottom), p values were calculated by Pearson
correlation.
(D) KPN/KP-score or expression of TGFB2 in human adenoma.
(legend continued on next page)
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significant increase of circulating neutrophils (Figure S7M).
Intriguingly, Alk5i treatment had no effect on circulating
neutrophils but significantly reduced neutrophils infiltrating me-
tastases (Figures 7H and 7I). In addition, we detected an in-
crease in activated CD69+/CD4+, CD69+/CD8+, and IFNg+
CD4+ type 1 T helper (Th1) cells upon Alk5i treatment (Figure 7J).
Importantly, we detected increased CD8+ GzB+ cytotoxic T
lymphocytes in metastases treated with Alk5i or CXCR2sm (Fig-
ures 7J, S7N, and S7O). This suggests that the effect of
CXCR2sm and Alk5i on metastasis is mediated by alleviation
of a neutrophil-dependent immunosuppressive microenviron-
ment. This is supported by the finding that CXCR2sm or Alk5i
have no effects on metastasis when KPN organoids were
transplanted into immune-deficient nude mice which lack
T cells (Figure S7P). Together, these data show that the epithe-
lial programs driven by NOTCH1 in KPN tumor cells rewire
the TME and generate an immunosuppressive, pro-metastatic
environment.
Inhibition of Neutrophil TGF-b Signaling Attenuates
Metastasis
Given the NOTCH1-dependent expression of Tgfb2 in the KPN
model and the profound effect on metastasis in the transplanta-
tion model, we examined the importance of TGF-b signaling to
NOTCH1-dependent metastasis. We confirmed TGF-b activity
in KPN tumors via nuclear localization of phosphorylated
SMAD3 (pSMAD3) and TGF-b signaling targets Smad7,
CALD1, and IGFBP7 (Figure 8A). We then applied two indepen-
dent, clinically relevant therapeutic approaches, either targeting
of TGFBR1/ALK5 with Alk5i, or with a ligand-trapping antibody
targeting TGF-b1/2/3 (1D11) (Figure 8B). In an early-intervention
setting, in which mice are treated from 85 days after induction,
inhibition of ALK5 resulted in rapid development of highly inva-
sive (T3) colonic tumors, althoughwith markedly reducedmetas-
tasis (Figures 8B and 8C; Table S1). Interestingly, targeting the
ligands with 1D11 did not result in accelerated tumorigenesis,
but significantly reduced metastasis (Figures 8B and 8C; Table
S1). In a late intervention approach, when mice were treated
with Alk5i from 130 days after induction, developing tumors
with a similar latency and comparable tumor burden as
vehicle-treated mice (Figures 8B and S8A), but with significantly
reduced metastatic penetrance at endpoint (Figure 8C; Table
S1). This was associated with a significant reduction in the num-
ber of neutrophils in the liver (Figure 8D), with peripheral blood
neutrophils being unaffected (Figure S8B). The reduction in liver
neutrophils was accompanied by accumulation of CD3+, CD4+,
and CD8+ T cells (Figures 8D, S8C, and S8D). Interestingly, no
change in primary tumor fibrosis was detected when KPN mice
were treated with Alk5i or 1D11 (Figure S8D). Taken together,
these data support a strong role for TGF-b signaling in gener-(E) qPCR from KP or KPN organoids (nR 3); normalized to Actb.
(F) GSEA plots of TGF-b activation (left, GSE15871; right, GSE39397) in KP vers
(G) Schematic representation of RBPJ binding sites at the mouse Tgfb2 promote
(H) Chromatin immunoprecipitation of RBPJ and IgG control in KPN organoids; n
two-tailed.
(I) Heatmap of marker expression across primary tumors.
(J) Representative images of Tgfb2 ISH in primary tumors. Scale bars, 100 mm.
Error bars in (D), (E), and (H) represent mean ± SEM. Data in (D) and (E) analyzed bating an immunosuppressive pro-metastatic microenvironment
in the liver by recruiting neutrophils.
To address the specific function of TGF-b signaling in the
neutrophil population of tumor-bearing mice, we transplanted
KPN organoids into the colonic submucosa of syngeneic
C57BL/6 mice lacking Alk5 expression specifically in Ly6G+ neu-
trophils (Ly6GCre Alk5fl/fl) (Figure 8E). Engrafted KPN organoids
formed primary tumors that were morphologically indistinguish-
able from those of the autochthonous GEMM (Figures 8F, S8E,
and S8F), with epithelial cells from primary tumors and liver
metastases also found to express high levels of Tgfb2 (Fig-
ure 8G). As predicted by inhibitor experiments, deletion of
Alk5 in the neutrophil population had no beneficial impact on sur-
vival (Figure S8G), but led to a striking reduction in metastasis
(Figure 8H). This was concomitant with reduced tumor-infil-
trating neutrophils, although peripheral blood neutrophil counts
were maintained (Figure 8I). Reduced neutrophil infiltration
was not associated with an alteration in neutrophil maturity, as
expression of CD101 (a marker of mature murine neutrophils)
was unaffected by ALK5 deficiency (Figure 8J). Importantly,
TGF-b signaling inhibition blocksmetastasis by reducing neutro-
phil attraction, rather than by polarization to an anti-tumor
phenotype.
DISCUSSION
The genetic progression of CRC has been investigated for many
years, yet no robust drivers of metastasis have been identified in
GEMMs. Importantly, we demonstrate that alteration of epithelial
tumor cell-intrinsic signaling can rewire the TME and, in turn, pro-
mote metastasis. Notably, this occurs spontaneously only in
concert with specific mutations that drive serrated tumors, and
not during the progression of WNT-driven tubular adenoma.
These observations are consistent with reported differential re-
sponses of tubular and serrated adenomas to TGF-b signaling
(Fessler et al., 2016).
Whole-genome sequencing of tumors from KPN mice re-
vealed relatively low levels of mutation, although recurrent bial-
lelic mutations in Csnk1a1 were observed. This would suggest
a further single sporadicmutation, for example inCsnk1a1, could
drive rapid progression to adenocarcinoma and metastasis in
the KPN model, possibly by generating an inflammatory TME
(Pribluda et al., 2013). One could hypothesize that this recapitu-
lates the ‘‘Big Bang’’ model of humanCRC inwhich the key driver
mutations occur early, while later, large tumors exhibit neutral
evolution (Sottoriva et al., 2015).
The literature regarding NOTCH and WNT interaction in WNT-
driven models reveals different roles of NOTCH1 signaling.
Epithelial N1icd expression, in combination with Apc1263 allelic
mutation, can drive tumor initiation (Fre et al., 2009), or inhibitus KPN organoids. ES, enrichment score; NES, normalized enrichment score.
r. TSS, transcription start site.
= 3 biological replicates of technical duplicates, analyzed by Student’s t test,
y Mann-Whitney U test, two-tailed. See also Figure S7 and Tables S7 and S8.
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Figure 7. TGF-b or CXCR2 Inhibition Attenuates KPN Metastasis via T Cell Activation
(A) Cartoon illustrating organoid isograft transplantation in the spleen.
(B) Quantification of macroscopic liver metastases 4 weeks post-transplantation; KPN, n = 4; AKPT, n = 5.
(C) Quantification of neutrophils in liver metastases by flow cytometry as in (B).
(D) Representative contour plots of the analysis performed in (C).
(E) Representative images for ISH analysis of Tgfb2 expression or IHC for Ly6G on liver metastases (nR 3). Scale bars, 100 mm.
(F) Schematic representation of the treatment regimen after organoid transplantation.
(G) Number and burden of macroscopic liver metastases 4 weeks post-KPN organoid transplantation; vehicle, n = 5; Alk5i, n = 5.
(H and I) Quantification of flow cytometry analysis for neutrophils in blood (H) or liver metastases 4 weeks post-KPN organoid transplantation (I); vehicle, n = 5;
Alk5i, nR 4.
(J) Quantification of flow cytometry analysis for T cell subsets in liver metastases 4 weeks post-KPN organoid transplantation; vehicle, n = 5; Alk5i, n = 4.
Error bars in (B), (C), (G), (H), (I), and (J) represent mean ± SEM. Data in (C), (G), (I), and (J) analyzed by Mann-Whitney U test, two-tailed. See also Figure S7.WNT signaling in the ApcMin/+ model at the transcriptional level
(Kim et al., 2012). Our results demonstrate that, in the context
of Apc and Trp53 loss, N1icd has no significant impact on sur-
vival or tumor stage. It is interesting to note, however, that we
observed reduced levels of selected WNT target genes in KPN
tumors and that a specific WNT pathway mutation was selected
in emerging tumors. Importantly, human serrated KRAS-mutant330 Cancer Cell 36, 319–336, September 16, 2019tumors predominantly exhibit low levels of nuclear b-catenin
(Bennecke et al., 2010), mirrored in KPN tumors. This demon-
strates that the model described here shares key cellular and
molecular features with human serrated disease. We speculate
that WNT ligand inhibition might be a therapeutic option for
this type of CRC as reported for CRC with RNF43 mutations or
R-spondin fusions (Storm et al., 2016; Yan et al., 2017; Han
(legend on next page)
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et al., 2017). This said, we found no response of these tumors to
PORCUPINE inhibition. From our work, it is interesting to pro-
pose that the timing of WNT pathway activation is key. When
Apc is lost early, adenoma/polyps are formed that require multi-
ple further mutations to progress to adenocarcinoma (Sakai
et al., 2018). In a serrated model, WNT pathway mutations occur
much later (which happens in the KPN model) and drive rapid
progression to carcinoma and metastasis.
Critically, our model suggests therapeutic targets in mCRC.
NOTCH inhibitors are currently in non-stratified clinical trials
for CRC and have shown some minor benefits (Andersson and
Lendahl, 2014; Meurette and Mehlen, 2018); our data suggest
benefits for NOTCH signaling inhibition in CMS4/CRIS-B
patients. Combinatorial inhibition of MEK/ERK and g-secretase
increases efficacy in melanoma, papillary thyroid cancer, and
CRC (Krepler et al., 2016; Yamashita et al., 2013; Schmidt
et al., 2018). Identification of tumors with activated NOTCH1
signaling may be aided with the KPN/KP-score described
here, or through use of TGF-b2 as surrogate. To generate the
NOTCH1 signature we activated N1icd in intestinal enterocytes,
mimicking the activation of NOTCH1 signaling in CRC by
NOTCH1 receptor copy gain (Arcaroli et al., 2016). Activation
of NOTCH1 in the KPN model had no impact upon normal ho-
meostasis, possibly because of targeted activation of NOTCH1
in adult tissue rather than during embryonic development (Fre
et al., 2005). Interestingly, lateral inhibition, which occurs in
the normal small intestinal crypt to maintain the stem cell niche,
could influence the dynamics of non-cell-autonomous NOTCH1
activation and may occur in malignant progression. This kind of
non-cell-autonomous activation should be considered in the
future.
Our work also elucidates a novel non-cell-autonomous role for
NOTCH1 in CRC through control of chemokine expression (TGF-
b2 and CXCL5). Interestingly, TGF-b2 shows a 100- to 500-fold
higher affinity to betaglycan/TGFBRIII than TGF-b1/3 (Cheifetz
et al., 1990). Previously, NOTCH1 signaling has been shown to
impact the cellular secretome of multiple cancers (Hoare et al.,
2016; Wieland et al., 2017; Shen et al., 2017). Interestingly, this
cancer-associated secretome includes many inflammatory che-
mokines, similar to the KPN tumors, such as granulocyte-colony
stimulating factor and interleukin-6. The potential release of
numerous chemokines may help to explain the dramatic effects
on neutrophils both in the blood and at metastatic sites in our
model. Non-metastatic KP tumors develop a similarly fibro-
blast-rich stroma as KPN tumors, but lack TGF-b2 expressionFigure 8. Inhibition of Neutrophilic TGF-b Signaling Attenuates Metast
(A) Representative images of indicated markers on KPN primary tumors. Scale b
(B) Schematic representation of treatment regime and Kaplan-Meier survival curv
day 130 , n = 12; 1D11 isotype day 85, n = 8; 1D11 day 85, n = 9; analyzed by lo
(C) Incidence of metastasis per indicated treatments: vehicle day 85, n = 11;
1D11 day 85, n = 8. Analyzed by chi-square test, two-tailed.
(D) Quantification of IHC for Ly6G+, CD4+, and CD8+ cells per KPN liver at endpo
(E) Cartoon illustrating intra-colonic transplantation of KPN organoids.
(F) Representative colonoscopy images 1 week post-transplantation. Arrows ind
(G) Representative ISH on transplanted KPN organoids. Scale bars, 100 mm.
(H) Incidence of metastases at endpoint; Alk5fl/fl, n = 14; Ly6GCre Alk5fl/fl, n = 13.
(I) Flow cytometry analysis of neutrophils in primary tumors (left) and peripheral b
(J) Flow cytometry analysis of CD101+ neutrophils in primary tumors; Alk5fl/fl, n =
Error bars in (D), (I), and (J) represent mean ± SEM, analyzed by Mann-Whitney U
332 Cancer Cell 36, 319–336, September 16, 2019and neutrophil infiltration. Therefore, the TME generated by
CAFs appears insufficient on its own to prime for metastasis
but relies on the infiltration of neutrophils. This suggests that
our GEMMs may differ from some of the recently described
models in which CAFs were important in defining TGF-b sensi-
tivity (Calon et al., 2012; Tauriello et al., 2018). Interestingly,
these models were initiated by Apc loss (alongside Kras, Tp53,
and Smad4/TgfbrII) and predominantly driven by transplantation
or induced colitis. It would be interesting to examine the chemo-
kine profiles of these tumors as they may well be differentially
dependent on contributions from components of the TME, as
indicated by the difference in TGF-b2 expression.
Though previously thought to be terminally differentiated cells,
neutrophils exhibit phenotypic plasticity and adopt distinct
mature phenotypes (Leach et al., 2019). Accordingly, neutrophils
have recently been shown to express variousmarkers ofmaturity
(Evrard et al., 2018). In particular, TGF-b signaling is thought to
be a key regulator of the pro-tumorigenic state of neutrophils,
and TGF-b inhibition has been shown to drive increased tumor
infiltration of neutrophils (Fridlender et al., 2009). This is in
contrast to our findings, where pharmacological inhibition of
TGF-b signaling and genetic deletion of TGF-b signaling activity
in neutrophils reduces neutrophil numbers in tumors but has no
effect on neutrophil maturation status.
Future studies should characterize the phenotypic traits of
neutrophils in themetastatic niche, when compared with the pri-
mary tumor and peripheral blood. Our findings suggest that
CXCR2/ALK5-expressing neutrophils are important in CMS4/
CRIS-B CRC disease progression and in the genesis of CRC
metastases. The unresponsiveness of primary tumors to
CXCR2sm treatment pre-clinically in this study and other
studies (Steele et al., 2016) might be explained by active im-
mune checkpoints in the primary site, which are lacking in the
metastatic site. It should be noted that our mouse model shows
high systemic levels of neutrophils and that clinically high
neutrophil-to-lymphocyte ratios (NLR) are often associated
with the poorest prognosis (Roxburgh et al., 2010). It would be
of interest to determine whether these NLRs could be used to
stratify patients for CXCR2/TGF-b/NOTCH-targeted therapies.
In particular, the sensitivity of metastases to neutrophil inhibition
holds promise as a potential treatment option for stage II/III CRC
patients with undergoing primary tumor resection before treat-
ment with CXCR2 or ALK5 inhibitors. Critically, we highlight a
novel targeted therapeutic approach which may compromise
the seeding of metastases in a setting in which major primaryasis
ars, 100 mm.
es of KPN mice treated with: vehicle day 85, n = 13; Alk5i day 85, n = 13; Alk5i
g rank (Mantel-Cox) test.
Alk5i day 85, n = 12; Alk5i day 130, n = 12; 1D11 isotype day 85, n = 8;
int (nR 4).
icate tumors.
Analyzed by chi-square test, two-tailed.
lood (right); Alk5fl/fl, n = 8; Ly6GCre Alk5fl/fl, nR 7.
6; Ly6GCre Alk5fl/fl, n = 5; MFI, mean fluorescence intensity.
test, two-tailed. See also Figure S8 and Table S1.
and metastatic tumor burden is reduced through surgical
resection.
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Oligonucleotides
ChIP and qPCR This paper Table S8
Software and Algorithms
GraphPad Prism software v7.03 GraphPad Software N/A
FlowJo v10.4.2. FlowJo N/A
HALO Image analysis software Indica Labs V2.0.1145
Other
BD LSRFortessa BD Biosciences N/A
IDEXX ProCyte Dx IDEXX N/A
SCN400F slide scanner Leica Microsystems N/A
Bond Rx autostainer Leica N/A
GentleMACS Octo Dissociator with Heaters Miltenyi Biotec 130-096-427
7500 Fast Real-Time PCR System Applied Biosystems N/A
AutostainerLink 48 Dako N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Requests for further information, reagents, and resources should be directed to and will be fulfilled by the Lead Contact, Owen J.
Sansom: (o.sansom@beatson.gla.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Species used: Mus musculus
Tumor Models and Treatments
All animal experiments were performed in accordance with a UK Home Office licence (Project License 70/8646), adhered to ARRIVE
guidelines andwere subject to review by the animal welfare and ethical review board of the University of Glasgow. Both genders were
induced with a single injection of 2 mg tamoxifen (Sigma-Aldrich, T5648) by intraperitoneal injection at an age of 6 to 12 weeks, all
experiments were performed on a C57BL/6 background (N = 5 or more). Mice were sampled at clinical endpoint, which was definede2 Cancer Cell 36, 319–336.e1–e7, September 16, 2019
as weight loss and/or hunching and/or cachexia. Mice were censoredR 550 days after tamoxifen administration or if sampled not
due to intestinal tumor burden or associated metastasis. The alleles used can be found in the Key Resources Table.
Alk5 inhibitor (Alk5i) (Anderton et al., 2011) (AstraZeneca, AZ12601011) was administered at 50 mg/kg and CXCR2 small molecule
(AstraZeneca, AZD5069) at 100 mg/kg, both in 0.5% Hydroxypropyl Methylcellulose (HPMC) and 0.1% Tween-80 twice daily by oral
gavage. As vehicle control for Alk5i andCXCR2sm0.5%HPMCand 0.1%Tween-80was givenwith the same regime. Ly6G-antibody
(clone 1A8, BioXcell, BE0075-1) or isotype control (clone 2A3, BioXcell, BE0089) were administered three times a week by intraper-
itoneal injection at 10 mg/kg. TGF-b ligand-antibody (clone 1D11, BioXcell, BE0057) or isotype control (clone MOPC-21, BioXcell,
BE0083) were administered three times aweek by intraperitoneal injection at 5mg/kg. LGK974 (Active Biochem, A-1400) was admin-
istered at 5 mg/kg, in 0.5% Methylcellulose (MC) and 0.5% Tween-80 twice daily by oral gavage. As vehicle control 0.5% MC and
0.5% Tween-80 was given with the same regime. Treatments were started 85 or 130 days after initial tamoxifen injection; short term
treatments of tumor bearing mice were started when tumors were palpable.
Patient Material
46 patients who underwent synchronous resection of colorectal primary tumor and liver metastases between April 2002 and June
2010 at Glasgow Royal Infirmary were included in the study, details can be found in Table S6. Patients were identified from a pro-
spectively maintained database and represent a consecutive cohort of resected patients. Application to access patient tissue
was approved by the NHS Greater Glasgow and Clyde biorepository and ethical approval granted in biorepository application
#357 and informed consent was obtained from all subjects. Patients were followed up at one month, six monthly until two years,
and thereafter annually until five years at which point they were discharged. Recurrence data, morbidity, and mortality was prospec-
tively collected. Information on date and cause of death was determined via access to the NHS Greater Glasgow and Clyde clinical
portal. Death records were complete until 1st November 2017, which served as the censor date.
Human liver metastases were anonymised, five micron-thick, formalin fixed and paraffin embedded sections of liver containing
metastatic colorectal carcinoma from partial hepatectomy specimens were stained for N1ICD. The use of the human material
was approved by the Lothian NRS Human Annotated Bioresource and informed consent was obtained from all subjects (ethical
review number 15/ES/0094).
METHOD DETAILS
Scoring of Tumor Stage and Differentiation
T staging of tumors was performed by a boarded pathologist according to the following parameters included in the classical TNM
classification; T0, no evidence of primary tumor. Tis, Carcinoma in situ: intraepithelial or invasion of the lamina propria (i.e. no exten-
sion through the muscularis mucosae and therefore the submucosa). T1, Tumor invades submucosa. T2, Tumor invades muscularis
propria. T3, Tumor invades into the subserosa. T4, Tumor invades/perforates the visceral peritoneum and into other adjacent organs/
structures.
Tumor differentiation scoring was performed by a boarded pathologist according to the following parameters; well differentiated
tumors exhibit clear glandular differentiation in >95% of the tumor. Moderately differentiated tumors exhibit glandular differentiation
in 50-95% of the tumor. Poorly differentiated carcinomas exhibit glandular differentiation in 5-50% of the tumor.
Blood Count Analysis
Blood was collected in EDTA columns after cardiac puncture. Blood samples were analyzed with IDEXX ProCyte Dx.
Organoid Culture
Advanced DMEM/F12 was supplemented with penicillin/streptomycin (100 U/ml / 100 mg/ml) (15140122), 2 mM L-Glutamine
(25030081), 10 mM HEPES (15630080), N2-supplement (17502001) and B27-supplement (17504044) (all ordered from Gibco, Life
Technologies or ThermoFisher-Scientific) and from here on is referred to as ADF. Complete ADF was prepared by supplementing
ADF with 50 ng/ml Recombinant Human EGF (Peprotech, AF-100-15), 100 ng/ml Recombinant Murine Noggin (Peprotech, 250-
38) and 500 ng/ml Recombinant Mouse R-spondin-1 (R&D systems, 3474-RS). Intestinal epithelium extraction (Faller et al., 2015)
and culture conditions were previously described (Sato et al., 2009). These culture conditions were used unless stated differently
in figure legends.
Tumors were cut into small fragments andwashed five times in PBS. Tumor fragments were incubated in 5ml 10x Trypsin (5mg/ml,
Gibco), 1x DNase buffer and 200U recombinant DNase I (Roche, 04716728001) at 37C for 30 minutes. To further dissociate tumor
fragments, 5 ml ADF was added and tumor fragments were shaken vigorously. This step was repeated five times. After aspirating the
supernatant and re-suspending the pellet in 10 ml ADF, the suspension was passed through a 70 mm cell strainer. The cell pellet was
re-suspended in Matrigel (BD Bioscience, 356231) according to pellet volume and seeded. Organoids/spheroids were cultured in
complete ADF at 37C, 5% CO2, 21% O2.
Single Cell Seeding
Organoids were harvested and dissociated by fiercely pipetting. Organoids were washed twice with PBS before being dissociated
into single cells by incubating in 2ml 10x Trypsin (5mg/ml), 1x DNase buffer and 200U recombinant DNase I (Roche, 04716728001) atCancer Cell 36, 319–336.e1–e7, September 16, 2019 e3
37C for 7minutes. Cells were passed through a 40 mmcell strainer before 1000 single cells were seeded in 20 ml Matrigel in a 24-wells
culture plate. LGK974 10 mM (Active Biochem, A-1400) and appropriate volumes of vehicle (DMSO) were added at the moment of
single cell seeding. Organoid forming capacity was assessed after one week by measurement of diameter and counting the number
of organoids formed in each culture condition.
Intra-Splenic Injection of Organoids
To prepare the cell suspension, KPN (liver metastases derived; C57BL/6, N=10) or villinCreER Apcfl/fl KrasG12D/+ Trp53fl/fl TrgfbrIfl/fl
(AKPT; small intestinal derived; C57BL/6, N=7) organoids were cultured in conditions as described above without R-spondin. Tumor
cells were harvested and washed with PBS and trypsinized with 0.25% Trypsin in PBS-EDTA for 7 minutes at 37C. After trypsiniza-
tion, cells were washed and passed through a 40 mm cell strainer and counted using a haemocytometer.
C57BL/6 or CD-1/Nude mice (6-12 weeks old males; Charles River, UK) were anesthetized with isoflurane, and a laparotomy was
performed to gain access to the spleen. 5x105 single cells in 50 mL PBS were injected into the spleen after which the incision was
sutured. The mice were sampled four weeks post transplantation. Organoid donor and recipient mice were sex matched.
Needle-Guided Intracolonic Organoid Transplantation
Colonic sub-mucosal injections of organoids were performed as previously described (Roper et al., 2017), using a Karl Storz TELE
PACK VET X LED endoscopic video unit. KPN liver metastases derived (C57BL/6, N=10) organoids, cultured in conditions as
described above without R-spondin, were harvested and dissociated by fiercely pipetting. Organoids were washed twice with
PBS before being injected. Approximately 500 organoids in 70 ml PBS were injected in a single injection. At clinical end point tumors
and metastasis were quantified.
Sample Processing and Staining for Flow Cytometry
Tumor samples were dissected and digested using the Mouse Tumor Dissociation Kit (Miltenyi Biotec, 130-096-730) and the
GentleMACS Octo Dissociator with Heaters (Miltenyi Biotec, 130-096-427), using the 37C_m_TDK_1 programme. The cells were
passed through a 70 mm cell strainer and then counted. Two million cells were stained with LIVE/DEAD fixable near-IR stain kit
(ThermoFisher, L10119) at 1:1000 dilution in 100 ml PBS in the dark for 20 minutes at 4C, then washed with PBS 1% BSA. TruStain
FcX anti-mouse CD16/32 (Biolegend, 101320) was used at 1:200 in 50 ml PBS 1% BSA to block CD16/32 activity, in the dark
for 15 minutes at 4C. After that incubation time, 50 ml of the antibody staining mixes were added: for the neutrophil panel, CD45
(ThermoFisher, 63-0451-82), CD48 (Biolegend, 103424), CD11b (Biolegend, 101243), Ly6G (BD Biosciences, 563978), and CD101
(ThermoFisher, 12-1011-82). For the T cell panel, CD45 (ThermoFisher, 63-0451-82), CD3 (Biolegend, 100228), CD4 (Biolegend,
100510), CD8a (Biolegend, 100730), and CD69 (Biolegend, 104508). The cells were incubated in the dark for 30 minutes at 4C.
The cells were thenwashedwith PBS and re-suspended in 50 ml PBS. To fix the cells, 50 ml of PBS 4%paraformaldehyde were added
to the re-suspended cells, followed by incubation at room temperature in the dark for 15 minutes. The cells were washed and re-sus-
pended in PBS. Only for the T cell panel, the cells were re-suspended in Permeabilization Buffer (ThermoFisher, 00-8333-56) instead.
The cells were stained intracellularly in 1x Permeabilization Buffer with IFNg (ThermoFisher, 25-7311-41), and Granzyme B (Bio-
legend, 515406) in the dark for 30 minutes at 4C. The cells were washed in Permeabilization Buffer. Finally, the cells were washed
in PBS and re-suspended in PBS for flow cytometry acquisition. Both neutrophil and T cell populations were identified with the
following initial gating strategy: doublet discrimination by discrepancy between FSC-A and FSC-H signals; live cells: CD45+. Subse-
quently, for neutrophils: CD48-/loLy6G+, CD11b+Ly6G+ to confirm the neutrophil identity, and CD101 to characterize the neutrophils.
Alternatively, for T cells: CD3+, and CD4+ and CD8+ subsets. For both subsets, CD69 was used to analyse for activation. For the CD4
subset, IFNgwas used as an additional activation marker, while Granzyme B was used for the CD8+ subset. The data were acquired
with the BD LSR Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJov10.4.2.
RNA Isolation
RNA was isolated using the Qiagen RNeasy Mini kit (Qiagen, 74104) according to the manufacturer’s protocol including the optional
DNA degradation step using the Qiagen RNase-Free DNase kit (Qiagen, 79254). Cell pellets or tissue were lysed using the Precellys
lysing kit (Bertin Instruments, KT03961-1-003-2) in a Precellys Evolution machine (Bertin Instruments).
Organoids of the respective genotype, at comparable passage ~ 5 were sampled 72 hours post seeding. Organoid pellets were
snap-frozen and RNA was isolated as described above.
RNA of whole tumor samples was isolated at endpoint from genotypes as indicated in figure legends and conserved in RNAlater
(Sigma, R0901) at -80C until further use for RNA isolation as described above. For sequencing tumor fragments were excised from
the tumor centre to minimize effects of intra-tumor heterogeneity. Primary tumors from KPN (villinCreER KrasG12D/+ Trp53fl/fl
R26N1icd/+; small intestine), KP (villinCreER KrasG12D/+ Trp53fl/fl; small intestine), APN (villinCreER Apcfl/+ Trp53fl/fl Rosa26N1icd/+; small
intestine) and AP (villinCreER Apcfl/+ Trp53fl/fl; small intestine) tumors were sampled without exclusion of submucosa or muscularis
propria.
qRT-PCR
cDNA was generated by reverse transcription of the isolated RNA using the M-MuLV-Reverse Transcriptase kit (ThermoFisher-Sci-
entific, 28025013) according to the manufacturer’s protocol. qPCR was performed using the DyNAmo HS SYBR Green qPCR kite4 Cancer Cell 36, 319–336.e1–e7, September 16, 2019
(ThermoFisher-Scientific, F410) according to the manufacturer’s protocol. CT-values were normalized to b-Actin (Actb) CT-values.
mRNA expression levels were calculated according to theDCTmethod and expressed as 2^(-DCT). Primers sequences can be found
in Table S8.
Chromatin Immunoprecipitation
For chromatin immunoprecipitation (ChIP) the SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology, 9005)
protocol was used according to the manufacturer’s instructions. In brief, KPN organoids were grown in medium conditions as
described above. Cells were cross-linked for 10 minutes at room temperature and chromatin was fragmented by micrococcus nu-
cleases followed by three sonication cycles to generate DNA fragments. Incubation with RBPSUH (D10A4) XP Rabbit mAb (Cell
Signaling Technology, 5313) or recommended concentration of rabbit normal IgG control (Cell Signaling Technology, 2729) for 16
hours at 4C was performed. The sequences of oligonucleotides used as qChIP primers are listed in Table S8.
Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin and processed by standard histology processing techniques. The following an-
tibodies were used: CD3 (AbCamAb16669, pH6 1:50), CD4 (eBioscience 14-9766-82, ER2 Leica, 1:500), CD8 (eBioscience 14-0808-
82, ER2 Leica,1:500), S100A9 (Santa Cruz sc-8115, pH6 1:1000), Ly6G (clone 1A8, 2B Scientific BE0075-1, ER2 Leica, 1:60000),
CD44 (BD Biosciences 550538, pH6, 1:250), SOX9 (Millipore AB5535, pH6, 1:500), b-catenin (BD Biosciences 610154, pH8,
1:50), MLH11 (Abcam ab92312, pH6, 1:200), CALD1 (Sigma HPA008066, ER2 Leica, 1:400), IGFBP7 (Sigma HPA002196, ER2 Leica,
1:100), pSMAD3 (AbcamAb52903, pH6, 1:40), aSMA (Sigma-Aldrich A2547, pH6, 1:25000), N1ICD (D3B8 Cell Signaling Technology
4147, Protaqs IX, BioCyc, 401603692, 1:50).
To stain collagen or fibrin presence within tissue sections Picro Sirius Red staining technique was used. Briefly, de-waxed
slides were immersed in Picro Sirius Red solution for 2 hours. Picro Sirius Red Solution: 0.1% Direct red 80 (Sigma, 41496LH) in
distilled water and 0.1% Fast green FCF (Raymond Lamb, S142-2) in distilled water were mixed in equal volumes and then diluted
1:9 with Aqueous Picric acid solution. Post staining slides were dehydrated according to standard protocols and mounted for
analysis.
Hypoxia was detected by administration of Hypoxyprobe (Hypoxyprobe HP1-100; 100 ml intraperitoneal) 1 hour before sampling
and detected using Hypoxyprobe recognizing antibody (Hypoxyprobe HP1-100, pH6, 1:150).
In Situ Hybridisation
In situ hybridisation (ISH) analysis was performed using the RNAscope 2.5 LS (Brown, 322100) detection kit (Advanced Cell Diagnos-
tics, Hayward, CA) on a Leica Bond Rx autostainer strictly according to the manufacturer’s instructions. Staining was performed on
4 mm formalin fixed paraffin sections which were cut and then placed in a 60C oven for 2 hours prior to staining. To ensure the quality
and integrity of the available RNA the tissue being investigated was tested with the positive control probe (mm-Ppib, 313918). Only
after probe quality control were the results evaluated. To further ensure accuracy and integrity of the staining a negative control probe
(mm-DapB, 312038) was used to confirm that the tissue staining seen was accurate due to binding with the target probe and not
non-specific. Probes: Cxcl1 (407728), Cxcl2 (437588), Cxcl3 (492758), Cxcl5 (467448), Cxcr2 (487678), Axin2 (400338), Lgr5
(312178), c-Myc (413458), Smad7 (429418), Tgfb1 (407758), Tgfb2 (406188), positive control probe Ppib (313918) and negative con-
trol probe DapB (312038).
RNA-Sequencing
The quality of the purified RNA was tested on an Agilent 2200 Tapestation using RNA screen tape. Libraries for cluster generation
and DNA sequencing were prepared following an adapted method from the Illumina TruSeq RNA LT Kit. Quality and quantity of
the DNA libraries was assessed on a Agilent 2200 Tapestation (D1000 screentape) and Qubit (Thermo Fisher Scientific) respectively.
The libraries were run on the Illumina Next Seq 500 using the High Output 75 cycles kit (2x36cycles, paired end reads, single index).
Quality checks on the raw RNA-Seq data files were done using fastqc version 0.11.2 and fastq_screen version 0.11.3. RNA-seq
paired-end reads were aligned to the GRCh38 (Church et al., 2011) version of the mouse genome using tophat2 version 2.0.13
(Kim et al., 2013) with Bowtie version 2.2.4.0 (Langmead and Salzberg, 2012). Expression levels were determined and statistically
analyzed by a combination of HTSeq version 0.6.1, the R environment, version 3.2.2, utilizing packages from the Bioconductor
data analysis suite and differential gene expression analysis based on the negative binomial distribution using the DESeq2
(Anders and Huber, 2010). All RNA-sequencing data have been deposited in the ArrayExpress database under accession number
E-MTAB-6363.
Tumor and Metastasis Scoring
Macroscopic intestinal tumor or metastases were analyzed for size and number and tumor burden or metastases burden was calcu-
lated as number of tumors times tumor size. All metastases were confirmed histologically.
Image Analysis
IHC and ISH (RNA-scope) images were digitalized using a SCN400F slide scanner (Leica Microsystems, Milton Keynes, UK) at 20x
(IHC) or 40x (ISH) resolution. Scanned images were analyzed using HALO Image analysis software (V2.0.1145, Indica Labs). TumorsCancer Cell 36, 319–336.e1–e7, September 16, 2019 e5
were analyzed for the percentage of positive cells for N1ICD, CD3, CD4, CD8a, Ly6G and S100A9. Tumor areas were manually
defined using the HALO software and scoring was performed in a blinded manner for all samples. b-catenin staining was analyzed
manually and considered as positive when > 10% of the tumor area was strongly positive for nuclear b-catenin.
For Cxcl5/Cxcr2 co-analysis serial sections (3.5 mm sections) were stained for Cxcl5 and Cxcr2 and scanned at 40x magnification.
Slides were then automatically aligned utilising the image registration module within the HALO package. Sequential, non-overlap-
ping, paired fields of view were then individually scored.
CRC Patient Data for In Silico Analysis
CRC patient data were obtained from different public sources. Expression data and clinical/genetic annotation from the TCGA proj-
ect (Cancer Genome Atlas Network, 2012) were downloaded from the FIREHOSE repository (https://gdac.broadinstitute.org/). This
included RNA-seq expression data generated by the Illumina HiSeq (n=326) and Genome Analyzer (n=172) platforms (RSEM normal-
ized data). After log transformation, data from both platforms were combined into a single dataset (n=498), by correcting platform-
specific effects with the ComBat algorithm (Johnson et al., 2007) as implemented in the sva R package (Leek et al., 2012). From the
NCBI GEO repository microarray expression data and clinical/genetic annotations for the following 11 datasets (total n=1981):
GSE39582 (n=585), GSE13294 (n=294), GSE14333 (n=157), GSE17536 (n=177), GSE17537 (N=55), GSE20916 (n=81), GSE2109
(n=315), GSE23878 (n=35), GSE33113 (n=90), GSE35896 (n=62) and GSE37892 (n=130). The microarray data were normalized,
summarized and log2 transformed using robust multiarray analysis (rma) and batch effects (both between and, where present, within
dataset) were removed using Combat. After normalization the probe sets were annotated using the hgu133plus2.db annotation R
package (Carlson, 2017). In the case ofmultiple probe sets interrogating a specific gene, the probe set with the highestmean intensity
was selected as representative for that gene. CMS labels for all datasets were obtained fromGuinney et al. (Guinney et al., 2015) and
CRIS labels were obtained from Isella et al. (Isella et al., 2017). A processed gene expression dataset of CRC liver metastases
(E-TABM-1112, n=120) was obtained from ArrayExpress.
Mouse Model and Patient Gene Expression Signatures
Mouse model gene expression signatures were generated by quantifying differential gene expression data using the DESeq2 R
package (Love et al., 2014). Patient-based CMS signatures were derived from the TCGA dataset where differential expression
was determined using the limma R package (Ritchie et al., 2015). Human-to-mouse orthologue mappings were obtained from
Biomart (http://biomart.org) (Smedley et al., 2015) using the interface provided by the biomaRt R package (Durinck et al., 2009).
In case of one-to-many human-to-mouse mappings the mapping with the highest homology percentage was selected. For the
mouse model-patient correlation analysis 75 genes were selected that were the up-regulated most significantly (> 0.75 log fold
change) in each of the four CMSs (300 genes total) and five CRISs (375 genes total) and calculated the Pearson correlation
coefficients of the mouse model signatures with the patient CMS and CRIS signatures.
Infiltration Scores
Infiltration scores were calculated with the MCPcounter R package (Becht et al., 2016a, 2016b) and then standardised per cell type.
KPN VS. APN Signature Survival Analysis
KPN (n=9) vs. APN (n=3) tumor and organoid KPN (n=3) and APN (n=4) gene expression signatures were determined using the same
procedure described in the previous paragraph. The 500 most significantly regulated genes were selected to construct the KPN vs.
APN signature. No formal p value cut-off was used but all Benjamini-Hochberg adjusted p valueswere below 1x10-6. TCGA andNCBI
GEO expression datasets (excluding samples of tumor stage IV, without recurrence data or those without a CMS label n=1018) were
combined into a single dataset correcting batch effect using ComBat. Expression values were mean-centred gene-wise and individ-
ual samples were scored by calculating the Pearson correlation coefficient with the KPN vs. APN signatures. Samples with a corre-
lation score > 0.1 were assigned to the positive group, those with a correlation score < -0.1 to the negative group. Kaplan-Meier plots
were generated using the survival R package and the survival distributions were compared with the log-rank test.
GSEA
Geneset enrichment analyses (GSEA) were run using the GSA R package with sample permutation (10,000 permutations) and gene
standardization using all genes in the expression dataset, taking the unadjusted p values as output. The input genesets are listed in
Table S5. The two TGF-b genesets used to asses TGF-b signaling activity in organoids where obtained from (Plasari et al., 2009;
Calon et al., 2012).
NOTCH-score
The NOTCH-score was calculated by summing the standardized expression of a panel of NOTCH related genes (Kwon et al., 2016):
JAG1, JAG2, DLL1, DLL3, DLL4, NOTCH1, NOTCH2, NOTCH3, NOTCH4, HES1, HES2, HEY1, HEY2 and DTX1. For the recurrence-
free survival analysis of CRC patients from the TCGA dataset, patients were stratified using the within-group median NOTCH-score.
KRASmutants were called whenmutations encoding amino acids G12, G13 and A143were present. Kaplan-Meier plots were gener-
ated using the survival R package and the survival distributions were compared with the log-rank test.e6 Cancer Cell 36, 319–336.e1–e7, September 16, 2019
WNT-score
The WNT-score was calculated by summing the standardised expression of a panel of WNT related genes: ASCL2, AXIN2, BMP4,
MRTO4, HILPDA, NOP16, KITLG, LGR5, MYC, NOP2, PPIF, SOX4, PAAF1, ZIC2 & ZNRF3.
KPN/KP-score
AKPN (n=3) vs. KP (n=3) organoid gene signature was generated by quantifying differential gene expression data using theDESeq2R
package. We selected the 100 most significantly up-regulated genes (log fold change > 1). No formal p value cut-off was used but all
Benjamini-Hochberg adjusted p values were below 1x10-2. The KPN/KP-score was calculated by summing the standardised expres-
sion of the genes in the KPN vs. KP score (Table S7).
Human Serrated Signature
The human serrated signature was derived by comparing WNT target gene expression (Van der Flier et al., 2007) in serrated and
tubular adenomas (GSE45270 (n=13) and GSE79460 (n=16)) (Fessler et al., 2016) using the limma R package. The microarray
data were normalized summarized and log2 transformed using robust multi array analysis (rma) and batch effects were removed us-
ing Combat. After normalization the probe sets were annotated using the hgu133plus2.db annotation R package. In case of multiple
probe sets interrogating a specific gene, the probe set with the highest mean intensity was selected as representative for that gene.
The mouse model signatures were generated using the DESeq2 R package (Love et al., 2014).
Whole Genome Sequencing
Organoid (tumor derived) and tail DNAwere extracted usingDNAeasy kit (Qiagen, 69504) as per themanufacturer’s instructions. DNA
concentration and quality were determined by Nanodrop spectrophotometry and by PicoGreen (Invitrogen, P11496). Whole genome
sequencing was performed using 151bp paired-end sequencing on the Illumina HiSeq X platform. Short insert libraries were con-
structed using prepared flow cells, and clusters generated using standard methods. Samples were sequenced at an average depth
of 39x with a minimum coverage of 26x. Data were mapped to the mouse reference genome (GRCm38) using the bwa-mem align-
ment tool (Li and Durbin, 2009). All whole genome sequencing data have been deposited in the European Nucleotide Archive (ENA)
under ENA accession ID: ERP040713.
Somatic Mutation Detection
Somatic variants were detected using CaVEMan, an expectation maximization–based somatic substitution detection algorithm
(Jones et al., 2016). Candidate somatic variants were then filtered for quality and to remove knownmouse genome variations (Keane
et al., 2011). Single point mutations overlapping known structural variants in any of the mouse genomes were also removed due to
high misalignment rates in these regions. Small insertion and deletion (indel) detection was performed using the cgp-pindel pipeline
(v0.2.4w) (Ye et al., 2009). Detected indels were then filtered for quality, sequence coverage in both tumor and normal, strand bias and
for overlap with known simple repeats or indels in the in-house normal panel. Selected mutations were confirmed by Sanger
sequencing.
Copy Number Detection
Tumor specific copy number changes were reported using Control free software (Boeva et al., 2012).
DATA AND CODE AVAILABILITY
The datasets generated during this study are available at the European Nucleotide Archive: ERP040713 and ArrayExpress:
E-MTAB-6363.
The codes supporting the current study have not been deposited in a public repository because of dependencies on in-house
software and data infrastructure, but are available from the corresponding author on request.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism software (v7.03 GraphPad software, La Jolla, CA, USA) and R (version
3.4.3) performing tests as indicated and were considered statistically significant, with * p<0.05, ** p<0.01, *** p<0.001, **** p<0.001.Cancer Cell 36, 319–336.e1–e7, September 16, 2019 e7
